文献速递胸部肿瘤妇科肿瘤消化系统肿瘤

肿瘤突变负荷与帕博利珠单抗治疗晚期实体瘤疗效的前瞻性生物标志物分析

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
PubMed 文献 · Lancet Oncol · 2020-09-10

KEYNOTE-158 是一项多队列、开放标签、非随机的 2 期研究,前瞻性评估组织肿瘤突变负荷(tTMB)与帕博利珠单抗疗效的关系。在 790 例可评估患者中,tTMB-high(≥10 突变/Mb)者客观缓解率为 29%,而 tTMB 非高者为 6%。tTMB-high 可识别对帕博利珠单抗单药有显著应答的亚组。

要点

  • tTMB-high(≥10 突变/Mb)患者客观缓解率 29%,非高者 6%。
  • tTMB 可能作为帕博利珠单抗单药疗效的新型预测生物标志物。
  • tTMB-high 患者中治疗相关严重不良事件发生率为 10%。

核心结论

  • tTMB-high 状态可识别对帕博利珠单抗单药有显著肿瘤应答的亚组患者。
  • tTMB 可能成为经治复发或转移性晚期实体瘤患者帕博利珠单抗单药疗效的新型预测生物标志物。

研究设计与样本

  • 多队列、开放标签、非随机、2 期 KEYNOTE-158 研究,纳入 21 个国家 81 家机构的患者。
  • eligible 患者为 18 岁及以上、组织学或细胞学确诊的晚期不可切除或转移性不可治愈实体瘤(肛管、胆道、宫颈、子宫内膜、间皮瘤、神经内分泌、唾液腺、小细胞肺癌、甲状腺、外阴),既往标准治疗进展或不耐受。
  • 患者接受帕博利珠单抗 200 mg 静脉每 3 周一次,最多 35 周期。
  • 组织 TMB 采用 FoundationOne CDx 检测福尔马林固定石蜡包埋肿瘤样本,tTMB-high 预设定义为至少 10 突变/Mb。
  • 主要终点为独立中心审查按 RECIST 1.1 评估的客观缓解比例。

主要发现

  • 2016 年 1 月 15 日至 2019 年 6 月 25 日入组 1073 例患者,数据截止 2019 年 6 月 27 日时 1066 例接受治疗。
  • 805 例(76%)可评估 TMB,其中 105 例(13%)为 tTMB-high 并纳入安全性分析。
  • 截至数据截止前至少 26 周入组的 1050 例(98%)患者中,790 例(75%)可评估 TMB 并纳入疗效分析。
  • 790 例中 102 例(13%)为 tTMB-high(≥10 突变/Mb),688 例(87%)为非 tTMB-high(<10 突变/Mb)。

关键数值与推荐

  • tTMB-high 组 102 例中 30 例(29%;95% CI 21-39)出现客观缓解。
  • 非 tTMB-high 组 688 例中 43 例(6%;95% CI 5-8)出现客观缓解。
  • 105 例 tTMB-high 患者中 11 例(10%)发生治疗相关严重不良事件。
  • 16 例(15%)发生 3-5 级治疗相关不良事件,其中结肠炎是唯一发生于超过 1 例患者的事件(n=2)。
  • 1 例患者发生致死性肺炎,研究者评估为治疗相关。

临床怎么用

  • 对经治晚期实体瘤患者,可考虑检测组织 TMB 以识别可能从帕博利珠单抗单药获益的 tTMB-high 亚组。
  • tTMB-high 患者使用帕博利珠单抗单药时客观缓解率较高,支持其作为预测生物标志物的潜在价值。

局限性

  • 本研究为非随机、开放标签设计,未设对照组。
  • 疗效分析仅纳入可评估 TMB 的患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2 KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with selected, previously treated, advanced solid tumours. METHODS: In the multi-cohort, open-label, non-randomised, phase 2 KEYNOTE-158 study, patients were enrolled from 81 academic facilities and community-based institutions across 21 countries in Africa, the Americas, Asia, and Europe. Eligible patients were aged 18 years or older, had a histologically or cytologically confirmed advanced (ie, unresectable or metastatic, or both) incurable solid tumour (eligible tumour types were anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small-cell lung, thyroid, and vulvar), progression on or intolerance to one or more lines of standard therapy, had measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) assessed by independent central radiological review, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at least 3 months, adequate organ function, and a tumour sample for biomarker analysis. Participants were given pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles. Tissue TMB (tTMB) was assessed in formalin-fixed paraffin-embedded tumour samples using the FoundationOne CDx assay (Foundation Medicine, Cambridge, MA, USA). The prespecified definition of tTMB-high status was at least 10 mutations per megabase. The primary endpoint was the proportion of patients with an objective response (complete or partial response) as per Response Evaluation Criteria in Solid Tumours (version 1.1) by independent central review. This prespecified analysis assessed the association between antitumour activity and tTMB in treated patients with evaluable tTMB data. Efficacy was assessed in all participants who received at least one dose of pembrolizumab, had evaluable tTMB data, and were enrolled at least 26 weeks before data cutoff (June 27, 2019), and safety was assessed in all participants who received at least one dose of pembrolizumab and had tTMB-high status. KEYNOTE-158 is registered at ClinicalTrials.gov, NCT02628067, and is ongoing. FINDINGS: Between Jan 15, 2016, and June 25, 2019, 1073 patients were enrolled. 1066 participants were treated as of data cutoff (June 27, 2019), of whom 805 (76%) were evaluable for TMB, and 105 (13%) of 805 had tTMB-high status and were assessed for safety. 1050 (98%) of 1066 patients enrolled by at least 26 weeks before data cutoff, of whom 790 (75%) were evaluable for TMB and included in efficacy analyses. 102 (13%) of these 790 patients had tTMB-high status (≥10 mutations per megabase), and 688 (87%) patients had non-tTMB-high status (<10 mutations per megabase). Median study follow-up was 37·1 months (IQR 35·0-38·3). Objective responses were observed in 30 (29%; 95% CI 21-39) of 102 patients in the tTMB-high group and 43 (6%; 5-8) of 688 in the non-tTMB-high group. 11 (10%) of 105 patients had treatment-related serious adverse events. 16 (15%) participants had a grade 3-5 treatment-related adverse event, of which colitis was the only such adverse event that occurred in more than one patient (n=2). One patient had fatal pneumonia that was assessed by the investigator to be treatment related. INTERPRETATION: tTMB-high status identifies a subgroup of patients who could have a robust tumour response to pembrolizumab monotherapy. tTMB could be a novel and useful predictive biomarker for response to pembrolizumab monotherapy in patients with previously treated recurrent or metastatic advanced solid tumours. FUNDING: Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020. PMID: 32919526. doi:10.1016/S1470-2045(20)30445-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。